Acumen Pharmaceuticals Future Growth
Future criteria checks 0/6
Acumen Pharmaceuticals's earnings are forecast to decline at 12.1% per annum while its annual revenue is expected to grow at 68.6% per year. EPS is expected to decline by 8.2% per annum. Return on equity is forecast to be -51.5% in 3 years.
Key information
-12.1%
Earnings growth rate
-8.2%
EPS growth rate
| Biotechs earnings growth | 24.1% |
| Revenue growth rate | 68.6% |
| Future return on equity | -51.5% |
| Analyst coverage | Low |
| Last updated | 04 Jul 2024 |
Recent future growth updates
Recent updates
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21
Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
Sep 28Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
Jun 30We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 01Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -107 | -138 | -138 | 2 |
| 12/31/2025 | N/A | -91 | -115 | -115 | 3 |
| 12/31/2024 | N/A | -70 | -68 | -68 | 3 |
| 3/31/2024 | N/A | -56 | -51 | -51 | N/A |
| 12/31/2023 | N/A | -52 | -43 | -43 | N/A |
| 9/30/2023 | N/A | -49 | -46 | -46 | N/A |
| 6/30/2023 | N/A | -46 | -42 | -42 | N/A |
| 3/31/2023 | N/A | -45 | -37 | -37 | N/A |
| 12/31/2022 | N/A | -43 | -35 | -35 | N/A |
| 9/30/2022 | N/A | -38 | -28 | -28 | N/A |
| 6/30/2022 | N/A | -32 | -26 | -26 | N/A |
| 3/31/2022 | N/A | -83 | -24 | -24 | N/A |
| 12/31/2021 | N/A | -101 | -18 | -18 | N/A |
| 9/30/2021 | 0 | -93 | -17 | -17 | N/A |
| 6/30/2021 | 1 | -92 | -11 | -11 | N/A |
| 3/31/2021 | 1 | -32 | -8 | -8 | N/A |
| 12/31/2020 | 1 | -7 | -7 | -7 | N/A |
| 12/31/2019 | 2 | -8 | -7 | -7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ABOS is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ABOS is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ABOS is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ABOS is forecast to have no revenue next year.
High Growth Revenue: ABOS is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ABOS is forecast to be unprofitable in 3 years.